APA (7th ed.) Citation

Ruggiero A, Fabbrocicni G, Cacciapuoti S, Potestio L, Gallo L, & Megna M. (2023). Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study. Dove Medical Press.

Chicago Style (17th ed.) Citation

Ruggiero A, Fabbrocicni G, Cacciapuoti S, Potestio L, Gallo L, and Megna M. Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study. Dove Medical Press, 2023.

MLA (9th ed.) Citation

Ruggiero A, et al. Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study. Dove Medical Press, 2023.